Anavex Life Sciences Corp. Agreement With The Roskamp Institute To Advance The Clinical Development Of ANAVEX PLUS

Published: Jan 13, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB:AVXL) today announced that they have established an agreement with The Roskamp Institute for the clinical development of ANAVEX PLUS, a new combination drug of ANAVEX 2-73 and donepezil (AriceptĀ®) for the treatment of Alzheimer's disease. This study will evaluate the safety, tolerability, pharmacokinetics, and possible clinical benefits of ANAVEX PLUS in Alzheimer's disease patients and other diseases associated with dementia and cognitive impairment.

Help employers find you! Check out all the jobs and post your resume.

Back to news